Skip to main content

Table 2 Demographic and baseline clinical characteristics in the parent studies

From: Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study

Characteristic Never Discontinued (n = 51) Discontinued (n = 42) All Patients (N = 93)
Reinitiated (n = 21) Not Reinitiated (n = 21)
Age, at first eculizumab dose, median (range), years 23.0 (0.0, 63.0) 21.0 (0.0, 65.0) 30.0 (0.0, 80.0) 21.0 (0.0, 80.0)
Age < 12 years, n (%) 15 (29) 5 (24) 6 (29) 26 (28)
Female, n (%) 30 (59) 11 (52) 16 (76) 57 (61)
Genetic or autoimmune complement abnormality, n (%)a 31 (61) 14 (67) 10 (48) 55 (59)
No. of TMA manifestations prior to first eculizumab dose, n (%)
 1 30 (59) 13 (62) 16 (76) 59 (63)
  ≥ 2 21 (41) 8 (38) 5 (24) 34 (37)
Time from most recent TMA manifestation to the first eculizumab dose, median (range), months 1.8 (0.0, 47.4) 0.4 (0.1, 37.8) 0.6 (0.0, 19.2) 0.9 (0.0, 47.4)
Time from aHUS diagnosis to first eculizumab dose, median (range), months 18.0 (0.0, 313.3) 3.0 (0.0, 191.4) 0.5 (0.0, 178.1) 4.0 (0.0, 313.3)
No. of PE/PI sessions at latest TMA manifestation before the first eculizumab dose, median (range) 13.0 (0.0, 230.0) 7.0 (0.0, 121.0) 7.0 (0.0, 64.0) 10.5 (0.0, 230.0)
Patients with dialysis at baseline of parent study, n (%) 18 (35) 11 (52) 9 (43) 38 (41)
Patients with renal transplant prior to first eculizumab dose, n (%) 14 (28) 4 (19) 5 (24) 23 (25)
  1. aHUS atypical hemolytic uremic syndrome; CFB complement factor B; CFH complement factor H; CFI complement factor I; MCP membrane cofactor protein; PE/PI plasma exchange/plasma infusion; TMA thrombotic microangiopathy
  2. aIncludes pathogenic variants in C3, CD46 (MCP), CFB, CFH, and CFI, as well as CFH autoantibodies as determined at enrollment in parent studies